Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, HSBC Analyst Says

Biogen (NASDAQ:BIIB) had its target price lifted by equities research analysts at HSBC from $143.00 to $150.00 in a report issued on Tuesday,MarketScreener reports. HSBC’s price target indicates a potential downside of 18.60% from the stock’s previous close.

Several other equities analysts also recently commented on BIIB. BMO Capital Markets increased their target price on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, February 6th. Wolfe Research set a $231.00 price target on Biogen in a research report on Monday, February 9th. The Goldman Sachs Group reiterated a “buy” rating on shares of Biogen in a research note on Monday, February 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th. Finally, Barclays assumed coverage on Biogen in a report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 target price for the company. Twelve equities research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. According to MarketBeat.com, Biogen presently has an average rating of “Hold” and an average price target of $205.31.

Biogen Price Performance

NASDAQ BIIB opened at $184.29 on Tuesday. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $27.05 billion, a PE ratio of 20.80, a price-to-earnings-growth ratio of 1.44 and a beta of 0.15. Biogen has a 12-month low of $110.04 and a 12-month high of $202.41. The company has a 50 day moving average price of $184.27 and a two-hundred day moving average price of $167.54.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities analysts predict that Biogen will post 15.83 earnings per share for the current fiscal year.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.18% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Empowered Funds LLC raised its stake in shares of Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after buying an additional 2,777 shares during the last quarter. Focus Partners Wealth raised its position in shares of Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after acquiring an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Biogen in the 2nd quarter valued at $216,000. Allworth Financial LP grew its stake in shares of Biogen by 114.3% during the second quarter. Allworth Financial LP now owns 2,179 shares of the biotechnology company’s stock worth $274,000 after purchasing an additional 1,162 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Biogen by 51.2% in the second quarter. PNC Financial Services Group Inc. now owns 38,089 shares of the biotechnology company’s stock worth $4,784,000 after acquiring an additional 12,894 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.